Crewe Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 24.3% in the second quarter, Holdings Channel reports. The firm owned 726 shares of the biopharmaceutical company’s stock after buying an additional 142 shares during the period. Crewe Advisors LLC’s holdings in Gilead Sciences were worth $80,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth about $25,000. Activest Wealth Management increased its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences during the second quarter worth about $27,000. Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth about $29,000. Finally, Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Gilead Sciences Stock Performance
NASDAQ:GILD opened at $122.81 on Monday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $152.38 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 0.84 and a beta of 0.34. The company’s 50-day moving average is $115.22 and its two-hundred day moving average is $110.51. Gilead Sciences, Inc. has a 1-year low of $85.60 and a 1-year high of $124.11.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer directly owned 595,725 shares in the company, valued at $67,692,231.75. The trade was a 1.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,500 shares of company stock worth $8,281,540 in the last ninety days. 0.27% of the stock is owned by insiders.
Analysts Set New Price Targets
GILD has been the subject of a number of research reports. Citigroup boosted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research note on Friday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald upped their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $119.17.
Check Out Our Latest Report on Gilead Sciences
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- What is an Earnings Surprise?
- JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Snap-on Incorporated: Snap It Up Quick, New Highs Will Come Soon
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- As Global Renewables Surpass Coal, This ETF Offers Smart Exposure
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.